The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1519
April 24, 2017
View Complete Issue         Table of Contents 2019 
Plecanatide (Trulance) for Chronic Idiopathic Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Plecanatide (Trulance) for Chronic Idiopathic Constipation
April 24, 2017 (Issue: 1519)
The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess), another guanylate cyclase-C receptor agonist, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Plecanatide (Trulance) for Chronic Idiopathic Constipation
Article code: 1519c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.